HAMPTON, Va.--(BUSINESS WIRE)--HST Global, Inc., (OTCBB:HSTC) announced today it is meeting with 72% efficacy in pre-clinical treatment of Stage IV cancer in a test of 250 patients. The highlight of the study is in stage IV breast cancer where they have met with 79% efficacy with 58 patients over 2 ½ years with its drug candidate Salicinium.
